Evidence map›Paper›PMID 15917519›Full record

Trial reportAntimicrobial agents and chemotherapy2005

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

John Weigelt, Kamal Itani, Dennis Stevens, William Lau, Matthew Dryden, Charles Knirsch, Linezolid CSSTI Study Group

Open access · greenAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 15 pooled it
23.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 15 syntheses or guidelines pooled it, 453 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Linezolid versus vancomycin for skin and soft tissue infections.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Systemic antibiotics for treating diabetic foot infections.The Cochrane database of systematic reviews · 2015
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. MRSA: treating people with infection.BMJ clinical evidence · 2010
    Pooled it
  12. Guideline
  13. Interventions for cellulitis and erysipelas.The Cochrane database of systematic reviews · 2010
    Pooled it
  14. Guideline
  15. Guideline
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

John WeigeltMedical College of Wisconsin, Milwaukee, Wisconsin 53226, USA. jweigelt@mcw.edu
Kamal Itani
Dennis Stevens
William Lau
Matthew Dryden
Charles Knirsch
Linezolid CSSTI Study Group
Boise VA Medical Center · USBoston University · USMedical College of Wisconsin · USPfizer (United States) · USRoyal Hampshire County Hospital · GBSt. Francis Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin and soft tissue infections (SSTIs) are a common cause of morbidity in both the community and the hospital. An SSTI is classified as complicated if the infection has spread to the deeper soft tissues, if surgical intervention is necessary, or if the patient has a comorbid condition hindering treatment response (e.g., diabetes mellitus or human immunodeficiency virus). The purpose of this study was to compare linezolid to vancomycin in the treatment of suspected or proven methicillin-resistant gram-positive complicated SSTIs (CSSTIs) requiring hospitalization. This was a randomized, open-label, comparator-controlled, multicenter, multinational study that included patients with suspected or proven methicillin-resistant Staphylococcus aureus (MRSA) infections that involved substantial areas of skin or deeper soft tissues, such as cellulitis, abscesses, infected ulcers, or burns (<10% of total body surface area). Patients were randomized (1:1) to receive linezolid (600 mg) every 12 h either intravenously (i.v.) or orally or vancomycin (1 g) every 12 h i.v. In the intent-to-treat population, 92.2% and 88.5% of patients treated with linezolid and vancomycin, respectively, were clinically cured at the test-of-cure (TOC) visit (P=0.057). Linezolid outcomes (124/140 patients or 88.6%) were superior to vancomycin outcomes (97/145 patients or 66.9%) at the TOC visit for patients with MRSA infections (P<0.001). Drug-related adverse events were reported in similar numbers in both the linezolid and the vancomycin arms of the trial. The results of this study demonstrate that linezolid therapy is well tolerated, equivalent to vancomycin in treating CSSTIs, and superior to vancomycin in the treatment of CSSTIs due to MRSA.

Indexed as

AcetamidesAdultAgedAnti-Infective AgentsFemaleHumansInternationalityLinezolidMaleMethicillin ResistanceMiddle AgedOxazolidinonesSkin Diseases, BacterialSoft Tissue InfectionsStaphylococcal InfectionsStaphylococcus aureusAcetamidesAnti-Infective AgentsLinezolidOxazolidinonesVancomycin

Identifiers

PMID15917519
PMCPMC1140485
OpenAlexW2090874066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.